Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhythm Pharmaceuticals Inc.

www.rhythmtx.com

Latest From Rhythm Pharmaceuticals Inc.

Rhythm Preparing NDA Submission In Rare Genetic Obesity Disorders

Setmelanotide reduced feelings of hunger in patients with POMC and LEPR deficiency obesities and helped many lose weight, with some caveats across certain endpoints.

Clinical Trials Rare Diseases

Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?

Public Company Edition: Is the IPO bubble getting ready to burst? It's anybody's guess, but biopharma companies are forging ahead, having launched 11 first-time offerings during the past week and a half. Also, Heron leads recent follow-on offerings with a $200m stock sale to fund what may soon be its third commercial product.

Financing Business Strategies

Pipeline Watch – Updates From EULAR, EHA and ECNP

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Clinical Trials

Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow

Allergan will spend 2018 trying to shift investor focus from the loss of Restasis patent exclusivity in the second half of the year to the company's R&D pipeline, including the late-stage "six stars" highlighted in 2017 and mid-stage programs that are moving into the spotlight.

Business Strategies Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • 1649904
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rhythm Pharmaceuticals Inc.
  • Senior Management
  • Keith M Gottesdiener, MD, CEO
    Hunter Smith, CFO
    Lex H Van der Ploeg, PhD, CSO
    Murray W Stewart, MD, CMO
    Nithya Desikan, Chief Commercial Officer
  • Contact Info
  • Rhythm Pharmaceuticals Inc.
    Phone: (857) 264-4280
    500 Boylston St., 11th Fl.
    Boston, MA 02116
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register